{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P07550",
      "entity_text" : "beta2-adrenergic receptor",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00641",
      "entity_text" : "3,4-DAP",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "We note that characterization of the CMS for individual 1 prompted treatment with 3,4-DAP, which blocks voltage gated potassium channels, and salbutamol, a beta2-adrenergic receptor agonist, which had good clinical effect.",
  "reading_complete" : "2020-08-08T09:48:41Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T09:45:51Z",
  "trigger" : "blocks",
  "evidence" : [ "3,4-DAP, which blocks voltage-gated potassium channels, and salbutamol, a beta2-adrenergic receptor" ],
  "pmc_id" : "4678414",
  "score" : 0
}